Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84

Benzinga Newsdesk www.benzinga.com Positive 80.9%

Neg 0% Neu 0% Pos 80.9%

Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $70 to $84.